Parasitic Infections Therapeutics
1. Alinia patent expiration
Treatment: Method of treating parasitic infections; Method of treating infection by cryptosporidium parvum in an immunocompromised mammal
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5968961 | ROMARK | Pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(8 years ago) | |
| US5578621 | ROMARK | Benzamide derivatives |
Sep, 2014
(11 years ago) | |
| US6020353 | ROMARK | 2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide |
Sep, 2014
(11 years ago) | |
| US6117894 | ROMARK | Acid stabilized pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(8 years ago) | |
| US5965590 | ROMARK | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
Jul, 2017
(8 years ago) | |
Drugs and Companies using NITAZOXANIDE ingredient
Market Authorisation Date: 21 July, 2004
Dosage: TABLET; FOR SUSPENSION
More Information on Dosage
ALINIA family patents
2. Artesunate patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12121506 | AMIVAS | Artesunate powders, pharmaceutical compositions and methods of manufacture |
Feb, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2025 |
| Orphan Drug Exclusivity(ODE-290) | May 26, 2027 |
Drugs and Companies using ARTESUNATE ingredient
NCE-1 date: 26 May, 2024
Market Authorisation Date: 26 May, 2020
Dosage: POWDER
More Information on Dosage
ARTESUNATE family patents